Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Endocrine Disorders » Adiponectin: Production, Regulation and Roles in Disease Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
_Cancer Research Journal - This journal ceased publication after 4#4 (2010). Back Issues are available.
$195.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Effect of losartan/hydrochlorothiazide on adiponectin and angiopathy-related markers in hypertensive patients with type 2 diabetes mellitus (pp.121-132)
Tell A Friend
 
Tell someone you know about this product.
Effect of losartan/hydrochlorothiazide on adiponectin and angiopathy-related markers in hypertensive patients with type 2 diabetes mellitus (pp.121-132) $0.00
Authors:  (Takayuki Kajiura, Kohichi Yamada, Ryotaro Ozasa, Shinya Fujita, Takashi Yokoi , Akira Shouzu, Norihito Inami, Seitarou Omoto, Takayuki Shimazu)
Abstract:
Angiotensin II receptor blockade has been shown to have a beneficial effect on the angiopathies of hypertension and hyperglycemia in patients with type 2 diabetes. On the other hand, blood pressure is difficult to control with monotherapy, especially in patients with diabetes, highlighting the requirement of drug contribution such as losartan/hydrochlorothiazide (LST/HCTZ). However, the effect of LST/HCTZ on the angiopathy-related markers in hypertension and type 2 diabetes is poorly understood. We investigated the effects of LST/HCTZ on these markers in 82 hypertensive patients with and without type 2 diabetes mellitus. Levels of the angiopathy-related markers (platelet-derived microparticles: 11.6 2.7 vs. 17.1 5.6 IU/ml, p < 0.01; RANTES: 73.1 12.2 vs. 88.8 20.4 ng/ml, p < 0.01; monocyte chemotactic peptide-1: 430 104 vs. 492 120 pg/ml, p < 0.05; and soluble E-selectin: 48 19 vs. 62 22 ng/ml, p < 0.01) were significantly increased in hypertensive patients with type 2 diabetes compared to without type 2 diabetes. In addition, the concentrations of adiponectin were significantly decreased in patients with type 2 diabetes (4.71 0.85 vs. 3.19 1.14 μg/ml, p < 0.01). Regardless of the presence of diabetic complications, both systolic and diastolic blood pressure significantly decreased after LST/HCTZ administration (LST/HCTZ 50 mg/day for 12 weeks). The angiopathy-related markers were decreased significantly in patients
with type 2 diabetes after LST/HCTZ treatment, but not in non-type 2 diabetic patients. In addition, LST/HCTZ alleviated hypoadiponectinemia in hypertensive patients with diabetes (before vs. after: 3.19 1.14 vs. 4.28 0.93 mg/ml, p < 0.01) but did not increase adiponectin levels in the non-diabetic hypertensive group, for which the average adiponectin level was normal prior to treatment. These results suggest LST/HCTZ may be beneficial as an adiponectin-dependent anti-atherosclerotic therapy in patients with type 2 diabetes in addition to its anti-hypertensive action. 


Available Options:
Version:

  Open Access item.
  Click below PDF icon for free download.

  

This is an Open Access item. Click above PDF icon for free download.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

Effect of losartan/hydrochlorothiazide on adiponectin and angiopathy-related markers in hypertensive patients with type 2 diabetes mellitus (pp.121-132)